Dr. Reddy’s settles Revlimid patent litigation with Celgene

Dr. Reddy’s today announced the settlement of their litigation with Celgene, a subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide) capsules.

In settlement of all outstanding claims in the litigation, Celgene has agreed to provide Dr. Reddy’s with a license to sell volume-limited amounts of generic lenalidomide capsules in the United States beginning on a confidential date after March 2022 subject to regulatory approval.

The agreed-upon percentages are confidential.  Dr. Reddy’s also is licensed to sell generic lenalidomide capsules in the United States without volume limitation beginning on Jan. 31, 2026.

“We are pleased with the settlement agreement, and look forward to bringing a generic version of lenalidomide to market soon subject to regulatory approval for the benefit of patients,” said Marc Kikuchi, Dr. Reddy's CEO, North America Generics.